Bosh sahifaEXEL • NASDAQ
add
Exelixis Inc
34,12 $
Seans yopilganidan keyin:(0,00%)0,00
34,12 $
Yopilgan:1-noy, 15:20:00 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
33,20 $
Kunlik diapazon
33,34 $ - 34,45 $
Yillik diapazon
19,21 $ - 34,45 $
Bozor kapitalizatsiyasi
9,73 mlrd USD
Oʻrtacha hajm
2,26 mln
Narx/foyda
21,74
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 539,54 mln | 14,33% |
Joriy xarajat | 334,37 mln | -28,97% |
Sof foyda | 117,97 mln | 11 232,66% |
Sof foyda marjasi | 21,87 | 9 840,91% |
Har bir ulushga tushum | 0,47 | 370,00% |
EBITDA | 195,30 mln | 1 830,28% |
Amaldagi soliq stavkasi | 23,77% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,19 mlrd | 7,77% |
Jami aktivlari | 2,96 mlrd | -0,56% |
Jami passivlari | 684,86 mln | 8,83% |
Umumiy kapital | 2,28 mlrd | — |
Tarqatilgan aksiyalar | 285,58 mln | — |
Narxi/balansdagi bahosi | 4,17 | — |
Aktivlardan daromad | 16,38% | — |
Kapitaldan daromad | 19,62% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 117,97 mln | 11 232,66% |
Operatsiyalardan naqd pul | 271,34 mln | 131,19% |
Sarmoyadan naqd pul | -217,15 mln | -726,05% |
Moliyadan naqd pul | 5,70 mln | 102,59% |
Naqd pulning sof oʻzgarishi | 59,89 mln | 188,56% |
Boʻsh pul | 302,21 mln | 913,29% |
Haqida
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
Tashkil etilgan
15-noy, 1994
Sayt
Xodimlar soni
1 310
